A moderately interesting paper was published in April 2021 by Adi Stern et al of Tel Aviv University titled “Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals” regarding the effectiveness of the Pfizer vaccine.
Vaccinees infected at least a week after the second dose were disproportionally infected with B.1.351 (odds ratio of 8:1). Those infected between two weeks after the first dose and one week after the second dose, were disproportionally infected by B.1.1.7 (odds ratio of 26:10), suggesting reduced vaccine effectiveness against both VOCs under different dosage/timing conditions.
Hang on, I thought vaccines are meant to protect you. (Please note that B.1.351 is Beta and B.1.1.7 is Alpha.)
But wait, that’s not all. Public Health England’s Technical Briefing 17, released June 25, is also interesting.
From Table 3, regarding Delta for <50 years of age, there has been 82,458 cases since February 1, of which 71,311 cases were in the past 28 days. For >=50 years of age, there has been 9,571 cases since February 1, of which 8,025 were in the past 28 days. Obviously, Delta is a recent thing in England.
From Table 4, out of the 82,458 cases for <50 years of age, 16,004 have received the first dose of the so-called vaccine and 3,689 have received the second dose. In other words, 23.9% of Delta cases for this age group have received at least one dose.
Out of the 9,571 cases for >=50 years of age, 3,953 have received the first dose of the vaccine and 3,546 have received the second dose. Thus, 78.4% of Delta cases for this age group have received at least one dose.
It seems that the so-called vaccine is not only ineffective against Delta, but it may somehow be facilitating infection. This, of course, requires further study but, at minimum, this vaccine seems to be as useful as a skinny decaf latte.
Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!
